Merck Serono Nonprofit Friends of Cancer Research Launches Public-Private HRD Harmonization Project The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients. FDA Gives Guardant Health IDE Approval for Clinical Trial of Merck KGaA Cancer Drug Guardant is providing its Guardant 360 CDx test for a clinical trial of Merck's small molecule, c-Met kinase inhibitor called tepotinib. Illumina, Merck Serono to Develop Universal NGS-based Oncology Dx The collaboration adds to a similar agreement Illumina struck with AstraZeneca, Janssen Biotech, and Sanofi last year. Spanish Cancer Institute Using Sysmex Inostics, Merck Serono Blood Dx to Study mCRC Personalized Rx Premium Vall d'Hebron's Institute of Oncology will use the liquid biopsy-based OncoBEAM RAS test to research precision medicine approaches for metastatic colorectal cancer patients. Comparison Shows Life Tech CastPCR Provides Equivalent Results to Therascreen for KRAS Detection Premium The customizable PCR plates may also be less expensive than the FDA-approved Therascreen kits. Jun 3, 2014 Merck KGaA, Sysmex Inostics Partner on Development of CRC Biomarker Test Jul 17, 2013 Merck Enlists Life Tech to Develop Companion Test for Cancer Drug, Other Pipeline Opportunities Premium Jul 16, 2013 Life Tech Inks Companion Dx Alliance with Merck Serono Sep 7, 2012 Merck Serono Spinoff Quartz Bio to Offer Specialized Biomarker Analysis Services to Pharma Premium Sep 3, 2012 Merck Serono Spins Out Bioinformatics Firm Jul 11, 2012 Merck KGaA, MDxHealth Explore Personalized Rx Strategy for Glioblastoma Patients with Methylated MGMT Premium Jul 3, 2012 Merck Serono, Compugen Form Joint Venture to Develop Genomic Tests for Drug-Induced Toxicity Premium Jun 25, 2012 Merck Serono, Compugen Form Biomarker Discovery Firm May 2, 2012 Merck Serono Survey Finds Limited Test Access, High Costs a Barrier to Personalized Rx Adoption in UK Premium Jan 20, 2011 Lead Discovery Center, Merck Partner on Kinase Inhibitor Discovery Jun 9, 2010 ASCO Reviewer Advises Genotyping to Improve Success for MEK-Inhibiting Cancer Drugs Premium Jun 10, 2009 BioSeek Extends Merck Profiling Plan to 2012 Mar 30, 2009 BioRegion Real Estate: Mar 30, 2009 Premium Mar 25, 2009 Tech Transfer Tidbits: Mar 25, 2009 Premium Breaking News FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery LGC Receives CE Mark for AccuPlex SARS-CoV-2, Flu A/B, RSV Reference Material Kit Esophageal Cancer Testing Firm Lucid Diagnostics Files For IPO Twist Bioscience, DeepCDR Collaborate on Antibody Library Design The Scan Booster for At-Risk The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk. Preprints OK to Mention Again Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications. Hundreds of Millions More to Share The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post. Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.